KRAS and neoplasm: Although this model can better simulate the tumor-immune interactions in immunocompetent mice, due to differences in the gene mutation spectrum compared with human PDAC, it cannot be used as a direct basis for translational therapy in human PDAC, but only provides a foundation for subsequent verification in more precise models (such as mouse models with driver gene mutations like KRAS and TP53).